United Therapeutics Corp
UTHR
$566.99
-0.28%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease. The company is a leader in the PAH space, with a portfolio largely built around the treprostinil molecule, and its distinct identity is that of a specialized, profitable biotech with a dominant position in its niche therapeutic area. The current investor narrative is heavily driven by positive late-stage clinical data for its lead drug Tyvaso in a new lung disease indication, as highlighted by a recent stock surge and news of a forthcoming FDA filing, which promises significant market expansion beyond its core PAH business.…
UTHR
United Therapeutics Corp
$566.99
Related headlines
Investment Opinion: Should I buy UTHR Today?
Rating & Thesis: Hold. UTHR presents a high-quality, profitable business with a binary, high-reward pipeline catalyst, but its current price largely reflects the optimistic scenario, balancing exceptional fundamentals against full valuation and execution risk. The bullish analyst consensus is supportive, but the wide target ranges indicate significant uncertainty.
Supporting Evidence: The company's trailing P/E of 16.2x is reasonable relative to its 46.1% net margin and the biotech sector. However, the Price/Sales ratio of 6.78x is elevated for a business with 7.38% revenue growth. The financial health is impeccable, with zero debt and a current ratio of 6.6. The stock trades at 93% of its 52-week high, showing strong momentum but also limited near-term upside based on technicals alone. The forward P/E of 17.4x is only slightly higher than the trailing multiple, suggesting modest near-term earnings growth expectations from the market.
Risks & Conditions: The two biggest risks are 1) commercial failure or delay of the Tyvaso expansion, and 2) valuation compression if revenue growth remains stagnant. This Hold rating would upgrade to a Buy if the stock pulls back to a more attractive valuation (e.g., P/E below 14x or a retreat toward the $500 support area) providing a better risk/reward entry, or if Q4 2026 earnings show clear acceleration from the new indication. It would downgrade to Sell if revenue growth decelerates further below 5% or if the Tyvaso FDA filing encounters significant, unexpected hurdles. The stock is currently fairly valued to slightly overvalued relative to its near-term fundamentals, with its price banking heavily on future pipeline success.
Sign up to view all
UTHR 12-Month Price Forecast
UTHR is a tale of two stories: a financially pristine, profitable but no-growth core business, and a high-potential pipeline bet that has already driven the stock up 87%. The current price appears to balance these narratives fairly, leaving the risk/reward skewed toward a 'wait-and-see' approach pending FDA and commercial execution. The low beta and strong balance sheet mitigate downside risk, but the elevated sales multiple leaves little room for error. The stance would upgrade to Bullish on a successful FDA approval coupled with a pullback to the $520-$540 range, offering a better entry point. It would downgrade to Bearish on any significant regulatory setback for Tyvaso.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $737.09 and implied upside of +30.0% versus the current price.
Average Target
$737.09
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$454 - $737
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, which is typical for a mid-cap biotechnology firm and can lead to higher volatility due to less efficient price discovery. The consensus sentiment among recent institutional ratings is bullish, with firms like TD Cowen, UBS, and Cantor Fitzgerald maintaining Buy or Overweight ratings, while Wells Fargo holds an Equal Weight stance, indicating generally positive but not unanimous conviction. The target price range implied by revenue and EPS estimates is wide, with estimated revenue for the next period spanning from $5.65 billion to $6.88 billion and EPS from $50.43 to $65.19, reflecting significant uncertainty and divergent views on the commercial success of pipeline expansions like Tyvaso's new indication.
Bulls vs Bears: UTHR Investment Factors
The bull case for United Therapeutics is anchored in its fortress financials, exceptional profitability, and a transformative pipeline catalyst that promises to break its revenue plateau. The bear case highlights the stock's dependence on that single catalyst, given its mature core business and elevated sales-based valuation. Currently, the bullish evidence appears stronger, supported by concrete fundamentals like a 46% net margin and zero debt, which provide a solid foundation for the speculative growth story. The single most important tension in the investment debate is the resolution of the Tyvaso expansion: its successful FDA approval and commercial launch could justify current valuations and drive the next leg up, while any delay or disappointment could trigger a severe derating given the lack of near-term organic growth.
Bullish
- Exceptional Profitability & Financial Health: The company boasts a net margin of 46.1% and gross margins consistently above 86%, demonstrating immense pricing power in its niche. This is supported by a pristine balance sheet with zero debt, a current ratio of 6.6, and over $1 billion in TTM free cash flow, providing a significant buffer and funding capacity.
- Major Pipeline Catalyst with Tyvaso Expansion: Positive Phase 3 data for Tyvaso in a new lung disease indication has driven a recent stock surge and sets up a major FDA filing. This represents a significant potential market expansion beyond the core PAH business, which is the primary driver of the current investor narrative and future growth expectations.
- Reasonable Valuation Relative to Fundamentals: With a trailing P/E of 16.2x, UTHR trades near the midpoint of its historical range (8.7x to 27x) and is at or below the typical biotechnology sector average. This valuation appears reasonable given its high profitability and strong balance sheet, offering a margin of safety.
- Strong Long-Term Momentum & Low Volatility: The stock has gained 87.08% over the past year and is trading near its 52-week high, indicating powerful bullish momentum. Notably, its beta of 0.595 suggests it is approximately 40% less volatile than the market, an unusual and attractive trait for a biotech stock, indicating lower systematic risk.
Bearish
- Mature Core Business with Stagnant Revenue: Q4 2025 revenue grew only 7.38% YoY, and quarterly revenue has plateaued between $794M and $800M throughout 2025. This indicates the core PAH business is mature and not providing near-term growth, making the company entirely dependent on pipeline success for expansion.
- High Valuation Premium on Sales & Cash Flow: Despite a reasonable P/E, the stock trades at a Price/Sales ratio of 6.78x and a Price/Cash Flow ratio of 13.83x. These elevated multiples suggest the market is pricing in significant future growth, which may not materialize if the Tyvaso expansion faces commercial or regulatory setbacks.
- Technical Overextension & Short-Term Weakness: Trading at 93% of its 52-week range, the stock is technically overextended and susceptible to a pullback. This is corroborated by a negative 1-month price change of -1.56% and a -7.16% relative strength vs. the SPY, signaling short-term consolidation or profit-taking.
- Limited Analyst Coverage & High Forecast Dispersion: Only 5 analysts cover the stock, which can lead to less efficient price discovery and higher volatility. Furthermore, their revenue estimates for the next period span a wide range from $5.65B to $6.88B, reflecting significant uncertainty about the commercial trajectory.
UTHR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +87.08%. With a current price of $568.58, it is trading near the top of its 52-week range, approximately 93% of the way from its low of $272.12 to its high of $609.35, indicating strong momentum but also potential overextension. Recent momentum shows a slight divergence; while the 3-month change is a robust +20.04%, the 1-month change is negative at -1.56%, suggesting a short-term consolidation or pullback within the larger bullish trend, which is further supported by a negative 1-month relative strength of -7.16 against the SPY. Key technical support is anchored at the 52-week low of $272.12, though more immediate support lies near recent pullback lows around $464, while resistance is clearly defined at the 52-week high of $609.35. A breakout above this level would confirm the continuation of the primary uptrend, while a breakdown below key support could signal a deeper correction; the stock's beta of 0.595 indicates it is approximately 40% less volatile than the broader market, which is atypical for biotech and suggests lower systematic risk.
Beta
0.59
0.59x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$272-$609
Price range past year
Annual Return
+85.7%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | +4.0% |
| 3m | +17.5% | +8.2% |
| 6m | +19.0% | +11.5% |
| 1y | +85.7% | +24.3% |
| ytd | +14.1% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue growth is stable but modest, with Q4 2025 revenue of $790.2 million representing a 7.38% year-over-year increase; however, examining the quarterly trend from Q1 to Q4 2025 shows revenue fluctuating between $794.4M and $799.5M, indicating a plateau rather than acceleration, which tempers the near-term growth narrative. The company is highly profitable, with Q4 net income of $364.3 million and a robust net margin of 46.1%; gross margins are exceptionally high at 86.91% for the quarter and have consistently ranged between 87% and 89% over recent periods, demonstrating pricing power and efficient production within its specialty pharma model. Financial health is pristine, featuring a debt-to-equity ratio of 0, a strong current ratio of 6.6, and substantial free cash flow generation with TTM FCF of $1.04 billion; this fortress balance sheet, coupled with an ROE of 18.8%, provides ample internal funding for R&D and business development without financial risk.
Quarterly Revenue
$790200000.0B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given a positive net income of $364.3 million, the primary valuation metric is the P/E ratio. The trailing P/E stands at 16.2x, while the forward P/E is slightly higher at 17.4x, a narrow gap that suggests the market is pricing in only modest earnings growth expectations in the near term. Compared to the broader biotechnology sector, a trailing P/E of 16.2x is generally at or below the industry average, suggesting the stock is not trading at a significant premium despite its profitability and clean balance sheet; this relative valuation appears reasonable given the company's stable but low-single-digit revenue growth profile. Historically, the stock's own trailing P/E has ranged from a low near 8.7x in early 2024 to a high above 27x in late 2025; the current multiple of 16.2x sits near the midpoint of this range, indicating the market is neither excessively optimistic nor pessimistic, balancing growth prospects from pipeline catalysts against the mature core business.
PE
16.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage or cash burn, but growth stagnation. Revenue has plateaued around $800M per quarter, with only 7.38% YoY growth in Q4 2025, indicating the core business is mature. While the company generates over $1 billion in annual free cash flow, its valuation (P/S of 6.78x) depends on successfully commercializing new indications like Tyvaso's expansion. A failure to translate pipeline success into accelerated top-line growth would compress these premium multiples. The concentration risk is significant, as the company derives maximum revenue from Tyvaso DPI, making it vulnerable to any competitive, pricing, or efficacy challenges specific to that product.
Market & Competitive Risks: The stock trades at a premium on sales and cash flow metrics, making it vulnerable to valuation compression if growth expectations are not met. The recent 87% price surge has likely pulled forward much of the optimism around the Tyvaso data, increasing sensitivity to any negative news. As a biotechnology firm, it faces inherent regulatory risk with the upcoming FDA filing for Tyvaso's new indication. While its low beta of 0.595 suggests limited macro sensitivity, the stock could still be impacted by sector-wide rotations out of healthcare or growth stocks, especially if interest rates remain elevated.
Worst-Case Scenario: The worst-case scenario involves a regulatory setback for the Tyvaso expansion, such as an FDA Complete Response Letter, coupled with increased competitive pressure in the core PAH market. This would shatter the growth narrative, leading to multiple compression. Analysts' low revenue estimate of $5.65B implies a more pessimistic commercial outlook. Given the stock's 52-week low is $272.12, a return to levels reflecting solely the mature, low-growth core business could imply a downside of approximately -52% from the current price of $568.58. A more immediate, realistic adverse scenario, based on the recent pullback low near $464, suggests a potential downside of -18% to -20% if technical support breaks.
FAQ
The key risks are, in order of severity: 1) Pipeline/Regulatory Risk: The stock's thesis hinges on FDA approval and successful launch of Tyvaso for a new indication; any delay or rejection would be severely negative. 2) Commercial Execution Risk: Even with approval, the company must demonstrate it can accelerate growth beyond its current plateau (~$800M/quarter). 3) Valuation Risk: With a P/S of 6.78x and trading at 93% of its 52-week high, the stock is vulnerable to multiple compression if growth disappoints. 4) Concentration Risk: Maximum revenue comes from Tyvaso DPI, creating dependency on a single product's performance.
The 12-month forecast is bifurcated, with a 50% probability Base Case target of $575-$625, a 30% probability Bull Case target of $650-$700, and a 20% probability Bear Case target of $450-$500. The Base Case, which is most likely, assumes FDA approval for Tyvaso's expansion but a gradual commercial ramp, leading to stable high-single-digit revenue growth. The key assumption is that the company successfully navigates the regulatory process and begins to show tangible revenue contribution from the new indication by late 2026, supporting its current valuation multiples without requiring a significant expansion.
UTHR is fairly valued to slightly overvalued based on near-term fundamentals, but its price includes a premium for future growth. Its trailing P/E of 16.2x is reasonable and below its historical high of 27x, especially given its high profitability. However, its Price/Sales ratio of 6.78x is elevated for a company with 7.38% revenue growth, indicating the market is paying for anticipated expansion from the Tyvaso pipeline. Compared to the biotech sector average, the P/E is not excessive. The valuation implies the market expects successful commercialization of Tyvaso's new indication to accelerate revenue meaningfully within the next 12-18 months.
UTHR is a good buy for a specific investor profile: those seeking a profitable, well-managed biotech with a near-term catalyst, and who can tolerate the volatility around FDA decisions. The stock offers a reasonable P/E of 16.2x supported by a 46% net margin and zero debt, but its premium P/S ratio of 6.78x is betting on future growth. The 52-week low of $272 provides a sense of the downside if the growth narrative fails, implying significant risk. For a diversified portfolio, it can be a tactical holding, but entering at current prices near the 52-week high offers a less compelling risk/reward than waiting for a pullback.
UTHR is suitable for a medium- to long-term investment horizon of 2-3 years, with a tactical short-term component around the FDA catalyst. The low beta of 0.595 and lack of a dividend make it less ideal for short-term trading or income seekers. The investment thesis requires time for the Tyvaso expansion to be approved, launched, and contribute to financials. However, the stock will likely see heightened volatility in the short term (next 6-12 months) around the FDA decision and initial launch metrics. Therefore, investors should be prepared to hold through potential volatility to realize the long-term growth story.